Managing inflammatory bowel disease in children and adolescents is a constant balancing act. Families and doctors look for ways to keep kids in remission while ensuring the medication stays effective in their systems. Recent data looks at what happens when these young patients switch from intravenous (IV) infusions to subcutaneous (under the skin) injections of the drug infliximab.
In a review of 162 patients, the results showed that the switch to subcutaneous injections helped maintain treatment persistence at nearly 90 percent. Additionally, about 90 percent of the children reached clinical remission at the six-month mark. The study also found that the amount of medicine in the blood roughly doubled after the switch, which helps keep the drug working effectively.
While the results are promising for maintaining treatment, the evidence is currently of low to very low certainty. It is important to note that this data only looks at patients already on the drug; it does not prove that starting the medication for the first time via injection will work the same way. Most children tolerated the switch well, with only a small number reporting minor issues like reactions at the injection site.
